NCT05493267 A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
| NCT ID | NCT05493267 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Condition | MDR-TB |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-08-03 |
| Primary Completion | 2025-08-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 30 participants in total. It began in 2022-08-03 with a primary completion date of 2025-08-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Eligibility Criteria
Inclusion Criteria: * RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin). * Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs. Exclusion Criteria: * Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc. * Test confirms poor response to ZOL and IL-2 stimulation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05493267 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying MDR-TB. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05493267 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05493267 currently recruiting?
Yes, NCT05493267 is actively recruiting participants. Contact the research team at 13671758200@126.com for enrollment information.
Where is the NCT05493267 trial being conducted?
This trial is being conducted at Shanghai, China, Shanghai, China.
Who is sponsoring the NCT05493267 clinical trial?
NCT05493267 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China. The trial plans to enroll 30 participants.